ARTICLE | Clinical News

Omnitarg pertuzumab: Phase II data

July 12, 2004 7:00 AM UTC

DNA said that in an open-label Phase II trial, Omnitarg monotherapy did not produce an objective response rate adequate for an accelerated approval or pursuit of a Phase III trial. DNA is planning a P...